

Screen Early for TMJ in Juvenile Idiopathic Arthritis

BY DIANA MAHONEY
New England Bureau

CHICAGO — Temporomandibular joint involvement is highly prevalent in children with new-onset juvenile idiopathic arthritis, but the absence of clinical symptoms or detectable swelling associated with the jaw condition in its early stages can delay diagnosis and timely treatment.

Recent studies have shown that as many as half, and possibly more, of all children with JIA have imaging evidence of temporomandibular joint (TMJ) arthritis, although few display clinical signs, such as impaired chewing ability, limited maximal mouth opening, pain, or crepitation, said Dr. Randy Q. Cron of the University of Alabama at Birmingham. "Usually we catch [TMJ arthritis] late, when we do some imaging because a patient's jaw looks smaller or is off center. Even though these kids have previously had normal findings on jaw examination, we see on MRI that they're pretty far gone in terms of effusions and condylar erosions."

To minimize the potential for micrognathia and malocclusion—and the associ-

ated aesthetic and functional sequelae of both—"screening for jaw involvement should be undertaken at the time of JIA diagnosis," Dr. Cron recommended. And because a history review and physical examination are insufficient screening measures, "medical imaging (specifically MRI, when possible) is required for an accurate diagnosis," he said.

Although there has been some suggestion that ultrasound might be a reasonable screening tool, a prospective study by Dr.


Pamela F. Weiss at the Children's Hospital of Philadelphia, Dr. Cron, and colleagues suggests that ultrasound is not up to the task. The study was designed to determine the point prevalence of TMJ arthritis at disease onset in children with JIA using both MRI and ultrasound, said Dr. Cron. A secondary aim "was to compare MRI versus ultrasound for diagnosing TMJ arthritis," he said.

The study included 32 children (median age, 8.6 years) diagnosed with JIA be-

tween January 2005 and April 2007 who were prospectively evaluated for TMJ arthritis via questionnaires and physical examination to assess jaw pain and disability. The TMJs of all of the patients were imaged with both MRI and ultrasound within 8 weeks of diagnosis (*Arthritis Rheum.* 2008;58:1189-96).

Of the 32 patients, 75% were diagnosed with acute TMJ arthritis by MRI; none of the cases was identified by ultrasound, said Dr. Cron. Chronic TMJ arthritis was de-

Indicated for treatment of signs and symptoms of OA or RA in patients at high risk of developing NSAID-induced gastric and duodenal ulcers and their complications



Intra-Articular Injection Pearls

For optimal safety and efficacy, CT-guided intra-articular corticosteroid injection of the TMJ of children with juvenile idiopathic arthritis should be performed in conjunction with an experienced pediatric interventional radiologist, stressed Dr. Randy Q. Cron.

The following technique, which was evaluated in a recently published study by radiologist Dr. Anne Marie Cahill of the Children's Hospital of Philadelphia, Dr. Cron, and colleagues, "is safe and technically successful, even in patients with joint space deformities," according to Dr. Cron.

► Position the child supine in CT scanner with head rotated 45 degrees away from the TMJ to be injected.

► Perform axial CT scan through the area of interest.

► Prepare access site anterior to tragus with povidone-iodine and alcohol and anesthetize it with 1% lidocaine using a 30-gauge needle.

► Use CT to confirm needle placement for steroid injection in mandibular fossa.

► Inject long-acting steroid (1 mL triamcinolone acetonide) into TMJ with an 18- or 21-gauge needle.

In the aforementioned investigation, all of the procedures were performed on an outpatient basis, and none of the known potential immediate reactions to intra-articular steroid injection—such as pain, headache, joint infection, or loss of subcutaneous fat—was observed, according to the authors.

When You Prescribe NSAIDs to Reduce Inflammation

Important Safety Information

ARTHROTEC is contraindicated in women who are pregnant or who may become pregnant. ARTHROTEC can cause miscarriage, often associated with bleeding, which may result in other serious complications.

Cardiovascular Risk

- NSAIDs may cause an increased risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk.

- ARTHROTEC is contraindicated for treatment of perioperative pain in the setting of coronary artery bypass graft (CABG) surgery.

Gastrointestinal Risk

- NSAIDs cause an increased risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients are at greater risk for serious gastrointestinal events.

ARTHROTEC is contraindicated in patients with hypersensitivity to diclofenac or to misoprostol or other prostaglandins and in patients who have experienced asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs. Severe, rarely fatal, anaphylactic-like reactions to diclofenac sodium have been reported.

The most common adverse events in ARTHROTEC-treated patients are abdominal pain (21%), diarrhea (19%), dyspepsia (14%), nausea (11%), and flatulence (9%), which can occur more frequently than with diclofenac alone.

Long-term administration of NSAIDs has resulted in renal papillary necrosis and other renal injury. Administration of NSAIDs may cause a dose dependent reduction in prostaglandin formation. Elevations in ALT and/or AST, and rare cases of severe hepatic reactions have also been reported. Transaminases should be monitored within 4-8 weeks after initiating treatment with diclofenac and should be measured periodically in patients receiving long-term therapy.

NSAIDs can cause serious skin adverse events such as exfoliative dermatitis, Stevens-Johnson syndrome, and toxic epidermal necrolysis, which can be fatal.

tected by MRI in 69% of the children, whereas ultrasound picked up chronic TMJ in only 28% of them, he said. Of the patients with acute TMJ arthritis, “more than 70% were asymptomatic and more than [60%] had normal findings on jaw examination, he noted.

The investigators also evaluated response to treatment with CT-guided intra-articular steroid injections among patients with TMJ arthritis identified on MRI, and determined that 56% of patients with acute disease—more than half of whom had been asymptomatic at baseline—had an improved maximal incisal opening after corticosteroid injection, said Dr. Cron.

In a previous retrospective study by the same research group, intra-articular corticosteroid injection was associated with increased mouth opening, decreased TMJ pain, and decreased TMJ effusions as detected by MRI in 23 patients in whom preinjection evidence of effusions (13 patients), bony erosions (19 patients), and condylar flattening (17 patients) was observed, Dr. Cron noted (Arthritis. Rheum, 2005;52:3563-9). Similarly,

Just because kids don't complain of pain does not mean there is not raging inflammation. ‘Most likely, there is, and we have to be ready to treat it.’

in a clinical review of a CT-guided percutaneous steroid injection technique in 15 JIA patients with TMJ arthropathy, the treatment resulted in substantial relief of clinical symptoms, when present, as well as resolution of related imaging abnormalities (AJR Am. J. Roentgenol. 2007; 188:182-6).


These findings suggest that treating TMJ arthritis before the onset of obvious bone changes, facial asymmetry, and limited mo-

bility can preserve normal jaw structure and function of JIA patients until they achieve disease remission, Dr. Cron said at a symposium sponsored by the American College of Rheumatology. Doing so, however, requires an awareness of the high prevalence of the condition as well as the implementation of a routine screening protocol in all new-onset JIA patients. “As clinicians, we see these patients every day. We have to remember that just because they’re not complaining about pain or problems [in their jaw], it does not mean there’s not inflammation that continues to rage on. Most likely, there is, and we have to be ready to treat it,” he said. ■



TAKE A CLOSER LOOK AT ARTHROTEC

- 1 **Misoprostol** protects gastric and duodenal mucosa
- 2 **Enteric coating** delays release of diclofenac until misoprostol has exerted its mucosal protective properties
- 3 **Diclofenac** relieves joint pain and inflammation



For patient starter kits, call 1-877-465-6437.

www.PfizerPro.com/Arthrotec

ARTHROTEC®
(diclofenac sodium/misoprostol)
50 and 75 mg tablets with 200 mcg misoprostol
Dual Action in a Single Pill

Please see brief summary of full Prescribing Information, including boxed warning, on adjacent pages.